Literature DB >> 16310518

Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver.

Daliana Peres Bota1, Marc Van Nuffelen, Ahmed N Zakariah, Jean-Louis Vincent.   

Abstract

Concentrations of C-reactive protein (CRP) and procalcitonin (PCT) have been suggested as markers of infection. The liver is believed to be a key source of CRP and PCT. For this reason we assessed the predictive value of these markers in patients with hepatic cirrhosis in a 31-bed university-hospital department of intensive care. Demographic, clinical, laboratory, and microbiologic data were collected prospectively over 9 months. Of 864 patients included in the study, 79 (9%) had hepatic cirrhosis. Patients with cirrhosis were more likely to have a medical than a surgical admission diagnosis (67 vs 47%, P = .03). They also had a higher rate of infection (48 vs 30%, P = .03) and higher mortality (44 vs 17%, P = .01) than did patients without cirrhosis. We detected no differences in CRP and PCT concentrations among patients with cirrhosis and different disease severity as assessed on the basis of Child-Pugh score. The serum CRP concentration (admission 11.2 +/- 4.6 vs 13.0 +/- 5.8, maximum 13.9 +/- 6.4 vs 18.8 +/- 7.3 mg/dL) and PCT (admission 1.3 +/- 0.9 vs 2.0 +/- 1.4, maximum 3.3 +/- 1.8 vs 3.4 +/- 2.1 ng/mL) were slightly lower in infected patients with cirrhosis than in infected patients without cirrhosis, but the differences were not statistically significant. Although the liver is considered the main source of CRP and a source of PCT, serum levels of these acute-phase proteins are not significantly lower in patients with cirrhosis than in other patients. Moreover, the predictive power of CRP and PCT for infection was similar for patients with and without cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16310518     DOI: 10.1016/j.lab.2005.08.005

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  33 in total

1.  Study of adiponectin in chronic liver disease and cholestasis.

Authors:  Tary A Salman; Naglaa Allam; Gasser I Azab; Ahmed A Shaarawy; Mona M Hassouna; Omkolsoum M El-Haddad
Journal:  Hepatol Int       Date:  2010-10-09       Impact factor: 6.047

2.  Epigallocatechin-3-gallate inhibits angiotensin II-induced C-reactive protein generation through interfering with the AT1-ROS-ERK1/2 signaling pathway in hepatocytes.

Authors:  Jingjing Zhao; Juntian Liu; Xiaoming Pang; Xiaolu Zhang; Shuyue Wang; Di Wu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-08-04       Impact factor: 3.000

3.  Impact of chronic liver disease in intensive care unit acquired pneumonia: a prospective study.

Authors:  Marta Di Pasquale; Mariano Esperatti; Ernesto Crisafulli; Miquel Ferrer; Gianluigi Li Bassi; Mariano Rinaudo; Angels Escorsell; Javier Fernandez; Antoni Mas; Francesco Blasi; Antoni Torres
Journal:  Intensive Care Med       Date:  2013-08-02       Impact factor: 17.440

4.  Association between C-reactive protein, incident liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study.

Authors:  Wen Chen; Jian-Bing Wang; Christian C Abnet; Sanford M Dawsey; Jin-Hu Fan; Liang-Yu Yin; Jian Yin; Philip R Taylor; You-Lin Qiao; Neal D Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-01-22       Impact factor: 4.254

Review 5.  New prognostic markers in liver cirrhosis.

Authors:  Vincent Di Martino; Delphine Weil; Jean-Paul Cervoni; Thierry Thevenot
Journal:  World J Hepatol       Date:  2015-05-28

Review 6.  Markers of bacterial translocation in end-stage liver disease.

Authors:  Ioannis Koutsounas; Garyfallia Kaltsa; Spyros I Siakavellas; Giorgos Bamias
Journal:  World J Hepatol       Date:  2015-09-18

7.  C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: a prospective cohort study.

Authors:  Kwok M Ho; Kok Y Lee; Geoffrey J Dobb; Steven A R Webb
Journal:  Intensive Care Med       Date:  2007-11-09       Impact factor: 17.440

8.  A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.

Authors:  Ahmed Abdel-Razik; Nasser Mousa; Hatem Elalfy; Tarek Fouad Sheta; Mahmoud Awad; Mostafa Abdelsalam; Rania Elhelaly; Rasha Elzehery; Nawal S Gouda; Waleed Eldars
Journal:  J Gastrointest Cancer       Date:  2017-03

9.  Plasma procalcitonin may be an early predictor of liver injury in acetaminophen poisoning: A prospective cohort study.

Authors:  Alexandre Nuzzo; Shireen Salem; Isabelle Malissin; Abdourahmane Diallo; Nicolas Deye; Antoine Goury; Hervé Gourlain; Nicolas Péron; Eric Vicaut; Sebastian Voicu; Bruno Mégarbane
Journal:  United European Gastroenterol J       Date:  2021-06       Impact factor: 4.623

10.  Procalcitonin in liver transplantation: are high levels due to donors or recipients?

Authors:  Daniel Eyraud; Saïd Ben Ayed; Marie Laure Tanguy; Corinne Vézinet; Jean Michel Siksik; Maguy Bernard; Sylvia Fratéa; Marie Movschin; Jean-Christophe Vaillant; Pierre Coriat; Laurent Hannoun
Journal:  Crit Care       Date:  2008-07-04       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.